RepliCel Life Sciences
 | |
| Type | Public limited company |
|---|---|
| Industry | Medical/Drugs |
| Trades as | OTCBB:REPCF |
| Website | http://www.replicel.com/ |
RepliCel Life Sciences Inc. (OTCBB:REPCF) trades as on the OTC Market Tier OTCQB [1]
Contents |
Corporate Overview
- About RepliCel
RepliCel Life Sciences is developing an autologous cell-based procedure for the treatment of androgenetic alopecia (pattern baldness) and general hair loss in men and women.Efforts are now focused on ensuring the safety and demonstrating the efficacy of RepliCel’s cell-based hair regeneration procedure in humans. The long-term goal is the development of a safe, evidence-based, minimally invasive procedure to treat various types of hair loss in men and women.
- Breakthrough Findings
RepliCel Life Sciences was founded to advance the breakthrough findings of Dr. Kevin McElwee and Dr. Rolf Hoffmann, established research scientists in the fields of immunology, hair biology, hair growth, and dermatology. In the early 2000s, at Phillips University in Marburg, Germany, Drs. McElwee and Hoffmann discovered that dermal sheath cup cells have the ability to initiate cellular growth of mature hair follicles in animals. RepliCel is now developing this discovery as a potential successful treatment for hair loss in humans.
In addition to the discovery of the critical cell population, RepliCel has created a proprietary method for extracting and, replicating dermal sheath cup cells, with the goal of developing a safe minimally invasive procedure for inducing natural hair growth in men and women suffering from various types of hair loss. The procedure has shown promise in pre-clinical trials, based on tissue engineering and laboratory models.
The procedure is now undergoing further rigorous study to establish safety and determine effectiveness. The first human clinical trial (Phase I/IIa) began in the country of Georgia in December 2010. Further clinical trials are planned for 2012 in Canada with European trials to follow.
http://www.replicel.com/about/corporate-overview/
History
- Two Decades of Research Collaboration
The founding scientists, Dr. Rolf Hoffmann and Dr. Kevin McElwee, have worked for more than two decades to develop a profound scientific understanding of immunology, hair biology, hair growth and alopecia. Their collaboration began in 1999 when Prof. Hoffmann appointed Dr. McElwee as a senior research scientist in the Department of Dermatology at Phillips University in Marburg, Germany.
The research collaboration led them to examine the dynamics of cultured hair follicle-derived cells focussing on a region of the hair follicle that had been largely ignored by scientists – the dermal sheath cup.In pre-clinical trials using tissue engineering and standard animal models, the scientists found that, in contrast to previous studies, cultured cells derived from the dermal sheath cup were capable of reconstituting a dermal papilla (“DP”) and promoting the development of hair follicles.
The scientists’ landmark study was published in the peer-reviewed Journal of Investigative Dermatology in 2003. Together, the scientists filed patent applications, which have been accepted in Europe and Australia and are now pending in the US, Canada, and Japan. Dr. McElwee was appointed to the Faculty of Medicine at the University of British Columbia in 2004. Two years later, he and Dr. Hoffmann founded TrichoScience Innovations Inc. (a wholly owned subsidiary of RepliCel Life Sciences Inc.) with three other internationally recognized hair research scientists – Drs. Jerry Shapiro, David McLean, Harvey Lui as well as a local entrepreneur Matt Wayrynen.
RepliCel is now focused on translating Dr. McElwee and Prof. Hoffmann’s scientific discoveries into a safe, non-surgical solution for treating androgenetic alopecia and other forms of hair loss in men and women. The company launched Phase I/IIa human clinical trials in Europe in December 2010. Further clinical trials are planned for 2012 in Canada with European trials to follow. Both Drs. McElwee and Hoffmann continue to play key leadership roles in the company. Dr. McElwee is RepliCel’s Chief Scientific Officer and Dr. Hoffmann is RepliCel’s Chief Medical Officer.
http://www.replicel.com/about/our-history/
Executive Team
- RepliCel’s Executive Team
RepliCel has attracted a seasoned, entrepreneurial management team with extensive experience in business management, the life sciences, and the pharmaceutical industry. Individual team members have established track records in their respective scientific or business fields.
:David Hall – CEO, President & Director
For more than a decade, Mr. Hall held executive management roles at Angiotech Pharmaceuticals Inc. including Chief Financial Officer, Chief Compliance Officer and Senior Vice President of Government & Community Relations. He also served as the company’s Corporate Secretary and Treasurer. Formerly Chairman of Life Sciences BC Biotech, Mr. Hall is highly committed to governmental policy issues related to the biotech industry. He is the former Chairman of the Biotech Industry Advisory Committee to the BC Competition Council, a past member of the BC Task Force on PharmaCare, and currently serves on the Board of the International Finance Centre BC. Mr. Hall is a member of the University of British Columbia’s Tech Equity Investment Committee and Director and Chairman of the Audit Committee of GLG Lifetech Corporation.
:Dr. Rolf Hoffmann, MD – Chief Medical Officer & Director
Dr. Hoffmann has been working for the past 18 years in the fields of alopecia, endocrinology of the hair follicle and hair follicle morphogenesis. He has published over 100 peer-reviewed medical and scientific journal articles, and has contributed to numerous dermatology textbooks. Dr. Hoffmann received his education in biochemistry and pathology at the University of Freiburg, Germany, one of Europe’s top centers for biology research. He is a board certified dermatologist and a Professor in the Department of Dermatology at Phillips University in Marburg, Germany. Dr. Hoffmann is the inventor of TrichoScan, the first GCP-approved, software-based, automatic technique to measure hair growth. He is a member of many scientific societies and worked several years as the secretary and president of the European Hair Research Society.
:Dr. Kevin McElwee, PhD – Chief Scientific Officer
Dr. McElwee, co-discoverer of the Company’s technology, is an Associate Professor in the Department of Dermatology and Skin Health at the University of British Columbia, and Director of the Hair Research Laboratory in the Vancouver Coastal Health Research Institute at Vancouver General Hospital (VGH). His research is funded by competitive grants awarded by multiple organizations including the Canadian Institutes for Health Research (the equivalent of the National Institutes for Health in the USA). Dr. McElwee is one of only a small group of research scientists worldwide who studies hair biology and associated diseases. He has worked as a hair research scientist for 12 years and has published over 70 medical journal articles, research abstracts and academic book chapters on hair loss research. Dr.McElwee received his Bachelor of Science degree from the University of Aberdeen, Scotland and his PhD from the University of Dundee, Scotland. Postdoctoral training included three years at the Jackson Laboratory in Maine and four years at the University of Marburg, Germany, studying various hair loss diseases.
:Tom Kordyback, CA – Chief Financial Officer
Tom Kordyback is a Chartered Accountant and a member of the British Columbia Institute of Chartered Accountants with over 25 years of experience in corporate finance and management for emerging growth companies. From 1984 to 1994, he held senior financial positions with Glenayre Electronics Inc. and Telelink Communications Inc. and worked as a consultant to other Vancouver area companies. In 1995, he began working for Creo, now part of Eastman Kodak Company as their Chief Financial Officer. In this role he oversaw private financings totally over $80 million and in 1999 he led the company’s Initial Public Offering on NASDAQ. He remained at Creo until 2000; at which time, the company had over 4000 employees worldwide. In 2004, Mr. Kordyback joined Extreme CCTV Inc., a developer and manufacturer of state-of-the-art surveillance systems listed on the TSX. He worked for them for three years as a director and member of its Audit, Compensation and Merger and Acquisitions Committees. In 2008 the company was sold to Bosch Security Systems, Inc. for CDN $93 million. Mr. Kordyback currently serves as a director of Silver Sun Resources Corp., a public Canadian-based resource company.
:Darrell Panich, MSc, PMP, CPM – Vice President, Clinical Affairs
An experienced clinical trial management specialist, Mr. Panich has managed multinational clinical research studies in more than 15 different countries for over 20 different pharmaceutical and biotechnology companies. He obtained his Master of Science degree from the University of Alberta while conducting clinical research in neuroscience. Mr. Panich has obtained certifications in project management from the Project Management Institute (Project Management Professional; PMP) and Project Management Leadership Group (Certified Project Manager; CPM).
:Gemma Bayley, CA – VP Finance & Corporate Secretary
Ms. Bayley is a Chartered Accountant and holds a degree in Economics from the University of British Columbia. Ms. Bayley has spent several years in public practice specializing in the brokerage industry, as well as audit and advisory work for both private and public clients. She recently held a senior management finance role with the Vancouver Organizing Committee for the 2010 Olympic and Paralympic Winter Games, and has a wide range of experience in accounting and finance.
:Tammey George – Director of Communications
Ms. George is a graduate of the Professional Communications program at Royal Roads University. She has more than 20 years of communications experience. From 1991 – 2001 she was the vice president of The Investor Relations Group, one of the largest investor relations firms on the West Coast. While there she directed all marketing and communications initiatives for corporate clients including re-branding, website design and optimization, TV and radio ads, print advertising, multimedia presentations and investor conferences. In 2001, she founded George Creative Consultants Inc. focused on public company communications. Ms. George is a member of the North American Investor Relations Institute and the Canadian Public Relations Society and has won awards for her marketing and communication programs.
http://www.replicel.com/about/leadership/executive-team
Intellectual Property
- RepliCel Patents
Patents for RepliCel’s proprietary method to isolate autologous dermal sheath cup cells for use in a hair regeneration procedure have been issued in the European Union and Australia. Patents are currently pending in the United States, Canada and Japan.
OUR SCIENCE
- Research Findings
Translating Findings Into a Potential Hair-Loss Solution Based at established universities in Canada and Germany, RepliCel’s scientific founders and research scientists have studied immunology, hair biology and hair growth for more than two decades. This respected team has developed a strong scientific understanding of the mechanisms underlying alopecia.
Collectively, the company’s scientific founders and research scientists are highly published in peer-reviewed scientific and medical publications in the areas of immunology, hair biology, hair growth, alopecia, hair follicle endocrinology and morphogenesis and clinical dermatology.
RepliCel’s current research activity is aimed at translating the scientific discoveries made by research scientists Drs. Kevin McElwee and Rolf Hoffmann. The scientists found that dermal sheath cup-derived cells carry the potential to induce the formation of new hair follicles in animals. Dermal sheath cup-derived cells were also found to induce better quality hair growth than cells derived from the dermal papilla(DP). The study suggested that dermal sheath cup cells are the source for the formation of the dermal papilla via all migration in natural hair follicle cycling.
This discovery provided the basis for a patent application in 2003, which has been accepted in Europe and Australia and is now pending in the US, Canada, and Japan. To learn more please read our scientist’s published paper in The Journal of Investigative Dermatology ©2003
http://www.nature.com/jid/journal/v121/n6/full/5602058a.html
Scientific / Medical Team
- Founding Scientists and Dermatologists
RepliCel was founded by a group of scientists and dermatologists from recognized academic research institutions with experience in immunology, hair biology, hair growth, alopecia, hair follicle endocrinology and morphogenesis, and clinical dermatology. Each scientist holds a long-established track record of research productivity.
:Dr. Rolf Hoffmann, MD – Founder
Dr. Hoffmann has been working for the past 18 years in the fields of alopecia, endocrinology of the hair follicle and hair follicle morphogenesis. He has published over 100 peer-reviewed medical and scientific journal articles, and has contributed to numerous dermatology textbooks. Dr. Hoffmann received his education in biochemistry and pathology at the University of Freiburg, Germany, one of Europe’s top centers for biology research. He is a board certified dermatologist and a Professor in the Department of Dermatology at Phillips University in Marburg, Germany. Dr. Hoffmann is the inventor of TrichoScan, the first GCP-approved, software-based, automatic technique to measure hair growth. He is a member of many scientific societies and worked several years as the secretary and president of the European Hair Research Society.
:Dr. Kevin McElwee, Ph.D. – Founder
Dr. McElwee has been an Associate Professor at the University of British Columbia since 2004, where he focuses on the diverse roles of the hair follicle in cutaneous disease and tissue regeneration. Dr. McElwee has over 70 peer-reviewed publications in professional scientific and medical journals and has authored several chapters in academic books on hair biology and immunology. Prior to joining the University of British Columbia, Dr. McElwee was a senior scientist at Phillipps University of Marburg in Germany and a Postdoctoral Fellow at The Jackson Laboratory in Bar Harbor, Maine. Dr. McElwee holds a Ph.D. in Cell Biology from the University of Dundee, Scotland, and a B.Sc. Hons. in Cell and Immunobiology – Zoology from the University of Aberdeen, Scotland.
:Dr. David McLean, MD, FRCPC – Founder
Dr. McLean is a Professor of Dermatology and the former Head of Dermatology at the University of British Columbia. He also serves as the Secretary-General of the International League of Dermatologic Societies and is on active staff at the British Columbia Cancer Agency, where he heads up Cancer Prevention. Dr. McLean has contributed to numerous start-up companies in his career and holds six US patents.
:Dr. Jerry Shapiro, MD, FRCPC – Founder
Dr. Shapiro is one of the most experienced hair dermatologists in the world and has specialized in hair disorders for the past 22 years. He holds dual academic appointments as Clinical Professor and Adjunct Professor at both the University of British Columbia and New York University School of Medicine. Dr. Shapiro is the founder of the first comprehensive integrated medical and surgical hair clinic in the world. He has trained over thirty international hair fellows from four continents. He has published over 100 peer-reviewed papers, 15 book chapters and two books. He has lectured internationally on hair related topics on 173 occasions on 6 continents.
:Dr. Harvey Lui, MD, FRCPC – Founder
Dr. Lui is the Medical Director of the Vancouver General Hospital Skin Care Centre, the largest medical facility in Canada devoted to dermatology. He is also the head of the Department of Dermatology and Skin Science at the University of British Columbia, which is the first and only academic dermatology department in Canada. After receiving his Bachelor of Science, Medical Degree, and Dermatology specialization from the University of British Columbia, Dr. Lui was a Clinical Fellow at the Massachusetts General Hospital, Harvard Medical School. Dr. Lui is a member of the American Board of Dermatology and the American Society for Laser Medicine and Surgery. Along with his duties at The Skin Care Centre and the University of British Columbia, he is also on staff at the BC Cancer Agency and the BC Children’s Hospital.
Investor Information
Market Data
- Corporate Name RepliCel Life Sciences Inc.
- Exchange OTCBB
- Symbol REPCF
- Shares Outstanding 40,550,006
- CUSIP # 76027P103
- Fiscal Year End December 31
- Date of Incorporation 1967
- Incorporated British Columbia, Canada
- Industry Life Sciences
- Transfer Agent Computershare
- Corporate Attorneys Clark Wilson LLP
- Auditors BDO Canada LLP
Contact Information
- Corporate Head Office: RepliCel Life Sciences
- 1225 – 888 Dunsmuir Street
- Vancouver, BC V6C 3K4
- Tel: 604-248-8730
- Toll Free: 1-800-248-5255
- Email: info@replicel.com
- Media and IR Contact: Tammey George, Director of Communications
- Direct: 604-248-8696
- Email: tg@replicel.com
- Clinical Trials Sign-Up:
Please visit our clinical trials sign-up page for more information.
http://www.replicel.com/contact-us/contact-information/ http://www.replicel.com/contact-us/email-alerts/ http://www.replicel.com/contact-us/clinical-trials-sign-up/
Corporate Publications
- Investor Fact Sheet:
http://www.replicel.com/wp-content/uploads/RepliCel-Fact-Sheet-Sept.pdf
Financial Publications: http://www.replicel.com/investors/corporate-publications/
Forward Looking
Official
Forward-Looking Statements http://www.replicel.com/disclaimer/
Certain statements on this website are forward-looking statements, including those that discuss strategies, goals, outlook or other non-historical matters; or project revenues, income, returns or other financial measures. Any action you take as a result of information, analysis, or advertisement provided on this site is ultimately your responsibility. Consult your investment adviser before making any decisions. Many of the “reference links” provided on this site are subject to change by the original content owners/providers. Information updated to this page is provided as-is on a volunteer basis, none of the authors can be assured the content they originally provided has not been modified and make no claims to future changes.
Fundamentals
RepliCel Links
- Equities Profile: http://www.equities.com/company-profile?s=REPCF
- Twitter Page: http://twitter.com/#!/@RepliCel/
- Investors Hub Page: http://ih.advfn.com/p.php?pid=squote&symbol=REPCF
- Youtube Page: http://www.youtube.com/RepliCel
References
Work in Progress
